Hematologic Malignancies Clinical Trial
Official title:
Analysis of KIR+CD56+ T Cells and FcRg-CD56+CD3- NK Cells in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients and Donors
Viral infections and reactivation during pediatric allogeneic hematopoietic stem cell
transplantation (HSCT) are a common occurrence and significantly contribute to
post-transplant morbidity and mortality. The risk is high due to prolonged periods of immune
deficiency while awaiting immune reconstitution post-transplant. Current strategies to reduce
complications from viral infections include prophylactic treatment, close monitoring for
viral infections and prompt treatment at the first sign of symptoms or increasing viral load.
However, the most definitive treatment for viral infections remains the host's cellular
defenses. Improved understanding of the immune systems response to viral infections may lead
to better treatment strategies.
This study is being done to explore the relationships between T-cells and NK cells (infection
fighting cells) and viral infections or reactivations in young allogeneic stem cell
transplant patients. The investigators will be looking at how these cells react and function
in young patients receiving allogeneic stem cell transplantation, as well as in healthy stem
cell donors.
PRIMARY OBJECTIVE:
- To explore the expansion patterns of KIR+CD56+ T-cells and FcRg-CD56+CD3- NK cells in
response to viral infection and reactivation in pediatric allogeneic hematopoietic stem
cell transplant (HSCT) patients.
SECONDARY OBJECTIVES:
- To describe the phenotype of KIR+CD56+ T-cells and FcRg-CD56+CD3- NK cells in pediatric
allogeneic HSCT patients and healthy donors.
- To describe the specificity and functional capacity of KIR+CD56+ T-cells against viral
antigens in both pediatric allogeneic HSCT patients and healthy donors.
- To describe the functional capacity of FcRg-CD56+CD3- NK cells against CMV-infected
cells in both pediatric allogeneic HSCT patients and healthy donors.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 |